Ionis Pharmaceuticals (IONS) Competitors $35.63 +0.04 (+0.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IONS vs. BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking. Does the MarketBeat Community favor BIIB or IONS? Biogen received 1112 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 71.76% of users gave Biogen an outperform vote while only 60.28% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes180771.76% Underperform Votes71128.24% Ionis PharmaceuticalsOutperform Votes69560.28% Underperform Votes45839.72% Does the media prefer BIIB or IONS? In the previous week, Biogen had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 19 mentions for Biogen and 16 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.76 beat Biogen's score of 0.12 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Ionis Pharmaceuticals 5 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIIB or IONS more profitable? Biogen has a net margin of 16.81% compared to Ionis Pharmaceuticals' net margin of -44.58%. Biogen's return on equity of 14.98% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.81% 14.98% 8.59% Ionis Pharmaceuticals -44.58%-88.98%-12.42% Do insiders and institutionals have more ownership in BIIB or IONS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.61B2.22$1.16B$11.0713.23Ionis Pharmaceuticals$803.07M7.01-$366.29M-$2.44-14.60 Which has more volatility & risk, BIIB or IONS? Biogen has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Do analysts rate BIIB or IONS? Biogen currently has a consensus price target of $242.68, suggesting a potential upside of 65.69%. Ionis Pharmaceuticals has a consensus price target of $60.65, suggesting a potential upside of 70.21%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 16 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.45Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.68 SummaryBiogen beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.63B$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-14.6010.55135.0817.16Price / Sales7.01194.011,120.30115.67Price / CashN/A57.1640.5837.88Price / Book13.205.104.754.78Net Income-$366.29M$151.51M$118.50M$225.60M7 Day Performance-2.68%-2.13%-1.85%-1.21%1 Month Performance5.34%-3.13%11.28%3.09%1 Year Performance-27.45%11.54%29.91%16.48% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.4165 of 5 stars$35.63+0.1%$60.65+70.2%-26.3%$5.63B$803.07M-14.60800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsHigh Trading VolumeBIIBBiogen4.6302 of 5 stars$150.99+0.6%$245.32+62.5%-41.0%$22.00B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7138 of 5 stars$370.14+2.3%$370.86+0.2%+59.5%$16.52B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8249 of 5 stars$134.26+6.0%$165.00+22.9%+12.6%$13.59B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7055 of 5 stars$70.37+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9838 of 5 stars$65.82-0.3%$94.20+43.1%-29.1%$12.54B$2.75B39.533,401Positive NewsEXASExact Sciences4.4907 of 5 stars$60.68-0.9%$72.94+20.2%-11.7%$11.23B$2.50B-52.356,600EXELExelixis4.5106 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0971 of 5 stars$159.42+1.9%$190.25+19.3%-19.7%$8.93B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$310.17+1.9%$347.33+12.0%+39.5%$6.76BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.47+1.0%$61.11+26.1%+29.1%$6.17B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors NBIX Competitors INCY Competitors BMRN Competitors EXAS Competitors EXEL Competitors RGEN Competitors MDGL Competitors HALO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IONS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
